Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Docetaxel (Taxotere) is a relatively new antineoplastic agent that is proving to be clinically useful in the treatment of a number of major solid tumors, including breast, ovarian, lung, and prostate carcinoma. Common systemic toxicities include neutropenia, alopecia, nausea, and vomiting. The authors report 5 patients (age range, 54-89 years) who experienced extravasation injuries with dramatic clinical presentations during peripheral intravenous administration of docetaxel. The authors did not find any other reported series of docetaxel extravasation in an extensive literature review. They present these 5 patients and provide treatment recommendations.
Ascherman
J A
JA
Department of Surgery, Columbia-Presbyterian Medical Center, Columbia University College of Physicians & Surgeons, New York, NY 10032, USA.
Knowles
S L
SL
Attkiss
K
K
D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D000077143:Docetaxel; D004487:Edema / Q000209:etiology*; D004890:Erythema / Q000209:etiology*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000628:therapy*; D006225:Hand; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000556:secondary; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel